Biocon Foundation marks 20 years of transforming lives
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
The observations issued are neither repeated observations nor related to data integrity
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025
Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Subscribe To Our Newsletter & Stay Updated